- Mesothelioma news are updated once a hour
- We deliver news from more than 500 sources on mesothelioma
NewsAdvertisers: |
Diagnostic Tools For Lung And Mesothelioma Cancers To Be Developed... Average five-year survival rates for patients diagnosed with lung cancer are less than 15%. Five year survival rates for patients with advanced stage IV lung cancer are only about 5%. The population at highest risk for lung cancer includes approximately 5 million men and women between the ages of 50 and 69 who are current or former smokers. By:
Rosetta Genomics Ltd on Apr 24 2007 10:14:53
Tell-a-Friend Add Your Comments Here
Print
RSS Feed
Home Cancer Treatment
... Rosetta Genomics Announces it has Presented Data on Advancements ......
Rosetta Genomics Ltd :: Rosetta Genomics Announces it has Presented Data on Advancements Made in the Company's Lead Assay Development Program for Cancer of Unknown Primary (CUP)
Rosetta Genomics Announces it has Presented Data on Advancements Made in the Company's Lead Assay Development Program for Cancer of Unknown Primary (CUP)
REHOVOT, Israel and NEW BRUNSWICK, New Jersey, April 20 /PRNewswire/ - Rosetta Genomics, Ltd. (NASDAQ: ROSG), announced today that it has presented updated results on its lead diagnostic development program for cancer of unknown primary (CUP), at the Annual Meeting of the American Association for Cancer Research (AACR), in Los Angeles, California. The poster, titled "MicroRNA Signature for Identification of Tumor Origin" presented the expansion of the company's CUP assay to include 15 major cancer types, identifiable through a unique signature of 19 microRNAs with 85% accuracy. In addition, data was presented regarding Rosetta Genomics' proprietary methods for extraction and profiling of microRNAs. The poster is available for viewing on the company's web site through the following link: http://www.rosettagenomics.com/_Uploads/UtilsMedia/AACR_April2007.jpg About microRNAs MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability t... New Treatment Yields Complete Regression Of A Human Cancer In Mice... PEGylation is a well-established process that is used in at least six protein-based pharmaceutical products currently on the market.PEGylated SS1Ps had fewer side effects and were more effective in mice bearing human tumors than standard SS1P, the report states. A single dose of the modified SS1P resulted in complete regression of the mouse tumors, the first time that such an effect had been observed, the researchers said. PEGylation of SS1P and other immunotoxins may hold promise for use in cancer patients, as well, they added.Article: "Releasable PEGylation of Mesothelin Targeted Immunotoxin SS1P Achieves Single Dosage Complete Regression of a Human Carcinoma in Mice" Note: This story has been adapted from a news release issued by American Chemical Society. New! Search Science Daily or the entire web with Google: Web ScienceDaily.com Print this page Bookmark Health Videos & Features Unusual Tumors in the Ovary Irene used to get red-faced at parties. But it wasn't until her doctor made the connection between her irregular periods and her flushing that she learned she had carcinoid syndrome. News: An Easier Way to Detect Bladder Cancer? Waiting to Treat Prostate Cancer? Can One Injection End Ho... 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news |